Entrada Therapeutics, Inc. (TRDA) Tops Q4 EPS by 4c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q4 EPS of ($0.94), $0.04 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $5.81 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters